Decreased presence of tubulin-GFP at axonal MTs in a pulse chase experiment suggests changes in MT replenishment with age. by Pilar Okenve-Ramos (18150546)

Decrease in accelerometer assessed physical activity during the first-year post-myocardial infarction: a prospective cohort study by Amanda Lönn (11583010)

A prepubertal CD decreases plasma leptin and cholesterol concentrations in adulthood despite a chronic HFD in Sprague-Dawley male rats. by Ana Aguilar-Lozano (20614619)

Significant decrease of SMAD4 protein in DBA iPSCs. by Jingping Ge (636557)

“…A) Slight decrease of mRNA level of <i>SMAD4</i> in the DBA iPSCs with <i>RPS19</i> or <i>RPL5</i> mutations. …”

A phenotype of increased sleepiness in a mouse model of pulmonary hypertension and right ventricular hypertrophy by Eric M. Davis (1733638)

“…After PAB, mice spent significantly more time in NREM sleep compared to the control group over a 24 hour period (53.5 ± 1.5% vs. 46.6 ± 1.4%; p < 0.01) and exhibited an inability to both cycle into REM sleep and decrease delta density across the light/sleep period. …”

Human adenovirus (HAdV) types HAdV-5 and HAdV-37 show decreased transduction efficiencies after treatment with cold atmospheric plasma (CAP). by Oskar Bunz (5900291)

Hyperalgesia was assessed by a decrease in paw withdrawal threshold (PWT_50%) in a model of mild heat injury (MHI). by Manuel P. Pereira (417488)

Cells with impaired Ssa2p•Mas5 complex have decreased cortical Cdc42 activity and exhibit monopolar intermittent growth pattern. by Aleksandar Vjestica (262087)

Decreased biomechanical stability of bones from <i>Col1a1-Krm2</i> transgenic mice. by Jochen Schulze (365258)

“…(D) Cortical thickness (C.Th.) and bone mineral density (vBMD) are decreased in <i>Col1a1-Krm2</i> transgenic mice compared to wildtype littermates. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

“…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”

Perioperative synbiotics administration decreases postoperative infections in patients with colorectal cancer: a randomized, double-blind clinical trial by ALINE TABORDA FLESCH (12724983)

Results from a clinical trial evaluating the efficacy of real-time body surface visual feedback in reducing patient motion during lung cancer radiotherapy by Gareth J. Price (2166580)

Administration of a Toll-Like Receptor 9 Agonist Decreases the Proviral Reservoir in Virologically Suppressed HIV-Infected Patients by Anni A. Winckelmann (407551)

Fig 5 - by Hannah N. Marmor (14046394)

Supplementary Material for: Association of Copeptin, a Surrogate Marker of Arginine Vasopressin, with Decreased Kidney Function in Sugarcane Workers in Guatemala by Butler-Dawson J. (8569992)

A R13A point mutation in C4 attenuates CLCuMuV infection. by Asigul Ismayil (5698946)

“…<b>(C)</b> The mutant CLCuMuV carrying C4^R13A (CLCuMuV-C4^R13A), which contains a R13A mutation in <i>C4</i>, showed the decreased viral symptom compared to wild type CLCuMuV. …”